HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review (Q30932448)

15 August 2017

1 reference

7 April 2021

HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review (English)

1 reference

Erb-b2 receptor tyrosine kinase 2

15 August 2017

1 reference

7 April 2021

1 reference

7 April 2021

1 reference

neoplastic gene expression regulation

18 December 2019

1 reference

gene expression profiling

4 November 2020

1 reference

7 April 2021

1 reference

1 reference

9

C Blomqvist

1 reference

15 August 2017

J Carlsson

1

1 reference

15 August 2017

H Nordgren

2

1 reference

15 August 2017

J Sjöström

3

1 reference

15 August 2017

K Wester

4

1 reference

15 August 2017

K Villman

5

1 reference

15 August 2017

N O Bengtsson

6

1 reference

15 August 2017

B Ostenstad

7

1 reference

15 August 2017

H Lundqvist

8

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 June 2004

1 reference

British Journal of Cancer

15 August 2017

14 June 2004

14 references

13 March 2019

3 April 2019

19 June 2019

17 June 2019

31 July 2019

2 August 2019

7 August 2019

8 September 2019

19 September 2019

28 September 2019

15 December 2019

18 December 2019

4 November 2020

7 April 2021

15 references

15 August 2017

13 March 2019

3 April 2019

19 June 2019

17 June 2019

31 July 2019

2 August 2019

7 August 2019

8 September 2019

19 September 2019

28 September 2019

15 December 2019

18 December 2019

4 November 2020

7 April 2021

90

1 reference

15 August 2017

12

1 reference

15 August 2017

2344-2348

1 reference

Advancing role of radiolabeled antibodies in the therapy of cancer

15 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409528

Tumour therapy with radionuclides: assessment of progress and problems.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409528

Current perspectives on HER2 testing: a review of national testing guidelines

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409528

Molecular prognostic factors for breast cancer metastasis and survival

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409528

A population-based study on the first forty-eight breast cancer patients receiving trastuzumab (Herceptin) on a named patient basis in Sweden

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409528

Liposome-based drug delivery in breast cancer treatment

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409528

The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409528

Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409528

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409528

Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409528

Amplification of c-myc oncogene by chromogenic and fluorescence in situ hybridization in archival breast cancer tissue array samples.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409528

Untangling the ErbB signalling network

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409528

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409528

The molecular biology of cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409528

Peptide receptor imaging and therapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409528

The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409528

Biomarker conservation in primary and metastatic epithelial ovarian cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409528

Receptor targeting for tumor localisation and therapy with radiopeptides

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409528

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409528

Conversion of a radioresistant phenotype to a more sensitive one by disabling erbB receptor signaling in human cancer cells

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409528

Increased level of c-erbB-2/neu/HER-2 protein in cutaneous squamous cell carcinoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409528

Stability of HER-2/neu expression over time and at multiple metastatic sites

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409528

Development of EGF-conjugated liposomes for targeted delivery of boronated DNA-binding agents

21 June 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6601881

Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6601881

Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6601881

Rationally designed anti-HER2/neu peptide mimetic disables P185HER2/neu tyrosine kinases in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6601881

C-erbB-2 expression does not predict response to docetaxel or sequential methotrexate and 5-fluorouracil in advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6601881

Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409528

HER-2--a possible target for therapy of metastatic urinary bladder carcinoma

25 November 2018

1 reference

12 December 2020

Assessment of Her-2/neu overexpression in primary breast cancers and their metastatic lesions: an immunohistochemical study

1 reference

12 December 2020

ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients

1 reference

12 December 2020

High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules

1 reference

12 December 2020

Are patterns of HER-2/neu amplification and expression among primary tumors and regional metastases indicative of those in distant metastases and predictive of Herceptin response?

1 reference

12 December 2020

Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer

1 reference

12 December 2020

c-erbB-2 protein overexpression and p53 immunoreaction in primary and recurrent breast cancer tissues

1 reference

12 December 2020

HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process

1 reference

12 December 2020

EGFR, c-erbB2 and p53 protein in the primary lesions and paired metastatic regional lymph nodes in breast cancer

1 reference

12 December 2020

Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites

1 reference

12 December 2020

Dimensions Publication ID

Identifiers

DOI

10.1038/SJ.BJC.6601881

0 references

0 references

1 reference

15 August 2017

1 reference